BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 32229068)

  • 1. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[
    Katzenellenbogen JA
    Nucl Med Biol; 2021 Jan; 92():24-37. PubMed ID: 32229068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Whole-Body Characterization of Estrogen Receptor Status in Metastatic Breast Cancer with 16α-18F-Fluoro-17β-Estradiol Positron Emission Tomography: Meta-Analysis and Recommendations for Integration into Clinical Applications.
    Kurland BF; Wiggins JR; Coche A; Fontan C; Bouvet Y; Webner P; Divgi C; Linden HM
    Oncologist; 2020 Oct; 25(10):835-844. PubMed ID: 32374053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 16α-18F-fluoro-17β-Fluoroestradiol (FES): Clinical Applications for Patients With Breast Cancer.
    Ulaner GA
    Semin Nucl Med; 2022 Sep; 52(5):574-583. PubMed ID: 35379454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 1b study evaluating the effect of elacestrant treatment on estrogen receptor availability and estradiol binding to the estrogen receptor in metastatic breast cancer lesions using
    Jager A; de Vries EGE; der Houven van Oordt CWM; Neven P; Venema CM; Glaudemans AWJM; Wang Y; Bagley RG; Conlan MG; Aftimos P
    Breast Cancer Res; 2020 Sep; 22(1):97. PubMed ID: 32912274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffuse bilateral
    Phillips EF; Karak PK
    J Med Imaging Radiat Sci; 2023 Dec; 54(4):726-731. PubMed ID: 37620179
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved Estrogen Receptor Assessment by PET Using the Novel Radiotracer
    Paquette M; Lavallée É; Phoenix S; Ouellet R; Senta H; van Lier JE; Guérin B; Lecomte R; Turcotte ÉE
    J Nucl Med; 2018 Feb; 59(2):197-203. PubMed ID: 28798032
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Summary: SNMMI Procedure Standard/EANM Practice Guideline for Estrogen Receptor Imaging of Patients with Breast Cancer Using 16α-[
    Mankoff D; Balogová S; Dunnwald L; Dehdashti F; DeVries E; Evangelista L; Van Kruchten M; Vaz SC; Fowler A; Linden H; Ulaner GA
    J Nucl Med; 2024 Feb; 65(2):221-223. PubMed ID: 38071554
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quantitative imaging of estrogen receptor expression in breast cancer with PET and 18F-fluoroestradiol.
    Peterson LM; Mankoff DA; Lawton T; Yagle K; Schubert EK; Stekhova S; Gown A; Link JM; Tewson T; Krohn KA
    J Nucl Med; 2008 Mar; 49(3):367-74. PubMed ID: 18287268
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacodynamic imaging guides dosing of a selective estrogen receptor degrader.
    Heidari P; Deng F; Esfahani SA; Leece AK; Shoup TM; Vasdev N; Mahmood U
    Clin Cancer Res; 2015 Mar; 21(6):1340-7. PubMed ID: 25609068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
    van Kruchten M; Glaudemans AW; de Vries EF; Beets-Tan RG; Schröder CP; Dierckx RA; de Vries EG; Hospers GA
    J Nucl Med; 2012 Feb; 53(2):182-90. PubMed ID: 22241912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
    Gemignani ML; Patil S; Seshan VE; Sampson M; Humm JL; Lewis JS; Brogi E; Larson SM; Morrow M; Pandit-Taskar N
    J Nucl Med; 2013 Oct; 54(10):1697-702. PubMed ID: 23970364
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [18F]-fluoroestradiol quantitative PET imaging to differentiate ER+ and ERα-knockdown breast tumors in mice.
    Paquette M; Ouellet R; Archambault M; Croteau É; Lecomte R; Bénard F
    Nucl Med Biol; 2012 Jan; 39(1):57-64. PubMed ID: 22079037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Summary: Appropriate Use Criteria for Estrogen Receptor-Targeted PET Imaging with 16α-
    Ulaner GA; Mankoff DA; Clark AS; Fowler AM; Linden HM; Peterson LM; Dehdashti F; Kurland BF; Mortimer J; Mouabbi J; Moon DH; de Vries EGE
    J Nucl Med; 2023 Mar; 64(3):351-354. PubMed ID: 36863779
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current applications of PET imaging of sex hormone receptors with a fluorinated analogue of estradiol or of testosterone.
    Talbot JN; Gligorov J; Nataf V; Montravers F; Huchet V; Michaud L; Ohnona J; Balogova S; Cussenot O; Daraï E; Lotz JP; Kerrou K
    Q J Nucl Med Mol Imaging; 2015 Mar; 59(1):4-17. PubMed ID: 25693420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully automated radiosynthesis and quality control of estrogen receptor targeting radiopharmaceutical 16α-[
    Wang M; Glick-Wilson BE; Zheng QH
    Appl Radiat Isot; 2020 Jun; 160():109109. PubMed ID: 32174461
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of the novel estrogen receptor PET tracer 4-fluoro-11β-methoxy-16α-[(18)F]fluoroestradiol (4FMFES) by PET imaging in a breast cancer murine model.
    Paquette M; Phoenix S; Ouellet R; Langlois R; van Lier JE; Turcotte EE; Bénard F; Lecomte R
    Mol Imaging Biol; 2013 Oct; 15(5):625-32. PubMed ID: 23619898
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
    Yang Z; Sun Y; Zhang Y; Xue J; Wang M; Shi W; Zhu B; Hu S; Yao Z; Pan H; Zhang Y
    Clin Breast Cancer; 2013 Oct; 13(5):359-63. PubMed ID: 23787040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Mortimer JE; Dehdashti F; Siegel BA; Katzenellenbogen JA; Fracasso P; Welch MJ
    Clin Cancer Res; 1996 Jun; 2(6):933-9. PubMed ID: 9816253
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PET-based estradiol challenge as a predictive biomarker of response to endocrine therapy in women with estrogen-receptor-positive breast cancer.
    Dehdashti F; Mortimer JE; Trinkaus K; Naughton MJ; Ellis M; Katzenellenbogen JA; Welch MJ; Siegel BA
    Breast Cancer Res Treat; 2009 Feb; 113(3):509-17. PubMed ID: 18327670
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgen and Estrogen Receptor Imaging in Metastatic Breast Cancer Patients as a Surrogate for Tissue Biopsies.
    Venema CM; Mammatas LH; Schröder CP; van Kruchten M; Apollonio G; Glaudemans AWJM; Bongaerts AHH; Hoekstra OS; Verheul HMW; Boven E; van der Vegt B; de Vries EFJ; de Vries EGE; Boellaard R; Menke van der Houven van Oordt CW; Hospers GAP
    J Nucl Med; 2017 Dec; 58(12):1906-1912. PubMed ID: 28912144
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.